NEW YORK (

TheStreet

) --

Celgene Corporation

(Nasdaq:

CELG

) hit a new 52-week high Friday as it is currently trading at $162.35, above its previous 52-week high of $161.64 with 905,772 shares traded as of 9:45 a.m. ET. Average volume has been 2.8 million shares over the past 30 days.

Celgene has a market cap of $64.09 billion and is part of the health care sector and drugs industry. Shares are up 98.2% year to date as of the close of trading on Thursday.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. The company has a P/E ratio of 44.7, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates

Celgene

TheStreet Recommends

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full

Celgene Ratings Report

.

See all

52-week high stocks

or get investment ideas from our

investment research center

.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more

.

null